The CheckMate-649 phase III trial found that, patients with advanced GC/GEJC treated with nivolumab, an anti-PD-1 antibody, obtained a survival benefit when combined with chemotherapy compared to chemotherapy alone in patients with tumors with PD-L1 CPS ≥ 1 and ≥5 [49]. This evidence concerns the gene CD274 and gastric cancer.